New partnership with Medvision for Medical Services Company brings the Gastrolyzer® range to Kuwait.
Bedfont® Scientific Limited, world leaders in breath analysis, is pleased to announce its collaboration with Medvision for Medical Services Company in Kuwait. Medvision, a leading distributor of high-quality medical equipment, disposables and services to the public and private sectors, has recently secured registration for the Gastrolyzer® range of Hydrogen-Methane Breath Testing (HMBT) devices.
The Gastrolyzer® range, manufactured by Bedfont®, an innovative med-tech company with over 48 years of experience in medical breath analysis, comprises of the Gastro+™ hydrogen breath testing device and the GastroCH4ECK™ HMBT device. These devices are designed to help detect gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO) and carbohydrate malabsorption, making them excellent additions to the Medvision catalogue.
“This registration and partnership represent a key milestone in our mission to expand globally while staying locally relevant,” said Jason Smith, CEO of Bedfont®. “Kuwait is a strategically important market for us, and with Medvision’s strong local expertise, we are confident that our HMBT range will reach and support the region with the quality and innovation they expect.”
Sharing high-quality and patient-focused values, this partnership marks a significant step in expanding Bedfont’s innovative technology in the Middle East. It will allow easier access and localised support for patients seeking reliable and advanced HMBT diagnostics.
The Gastrolyzer® range is now officially registered by Medvision, ensuring compliance with local regulations and streamlined access for end-users in Kuwait. For more information on the Gastrolyzer® range and how it revolutionises gastrointestinal investigation, click here.
